Global IDO Inhibitors Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
- SKU ID : GIR-GIR1808070020 12894571
- |
- Publishing Date: 27-Sep-2018
- |
- Region: Global
- |
- No. of pages: 101
The IDO (indoleamine 2,3-dioxygenase 1, IDO1, IDO-1, INDO, indoleamine-pyrrole 2,3-dioxygenase) inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global IDO inhibitors market. Most of the pipeline therapeutics are in early stage of development, the market is yet to witness first IDO inhibitor launch and its impact on overall oncology market.
Scope of the Report:
This report focuses on the IDO Inhibitors in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Indoleamine-2,3-dioxygenase (IDO) is one of the many immune checkpoints in tumor immune escape. Inhibiting IDO will help researchers restore immune system responses, which in turn, will help identify and destroy cancer cells. In addition to transforming the approach to treat advanced melanoma, the successful entry of IDO inhibitors in the market will also help transform the treatment of non-small lung cancer, triple-negative breast cancer, and bladder cancer with the existing therapies. Currently, most of the IDO inhibitors under investigation are in the very nascent development stage and focusing on R&D, pharmaceutical companies are making huge investments through collaboration agreements. For instance, one of the major pharmaceutical companies Pfizer has partnered with iTeos Therapeutics for the development of undisclosed IDO1 and tryptophan 2,3-dioxygenase 2 (TDO2) inhibitors.
The worldwide market for IDO Inhibitors is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
Pfizer
Bristol-Myers Squibb
Kyowa Hakko Kirin
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Dual IDO1/TDO inhibitors
Covalent IDO inhibitors
Market Segment by Applications, can be divided into
Metastatic Melanoma
Metastatic Pancreatic Cancer
mCRPC
Malignant Glioma
Astrocytoma
Breast Cancer
There are 15 Chapters to deeply display the global IDO Inhibitors market.
Chapter 1, to describe IDO Inhibitors Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of IDO Inhibitors, with sales, revenue, and price of IDO Inhibitors, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of IDO Inhibitors, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, IDO Inhibitors market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe IDO Inhibitors sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
Scope of the Report:
This report focuses on the IDO Inhibitors in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Indoleamine-2,3-dioxygenase (IDO) is one of the many immune checkpoints in tumor immune escape. Inhibiting IDO will help researchers restore immune system responses, which in turn, will help identify and destroy cancer cells. In addition to transforming the approach to treat advanced melanoma, the successful entry of IDO inhibitors in the market will also help transform the treatment of non-small lung cancer, triple-negative breast cancer, and bladder cancer with the existing therapies. Currently, most of the IDO inhibitors under investigation are in the very nascent development stage and focusing on R&D, pharmaceutical companies are making huge investments through collaboration agreements. For instance, one of the major pharmaceutical companies Pfizer has partnered with iTeos Therapeutics for the development of undisclosed IDO1 and tryptophan 2,3-dioxygenase 2 (TDO2) inhibitors.
The worldwide market for IDO Inhibitors is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
Pfizer
Bristol-Myers Squibb
Kyowa Hakko Kirin
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Dual IDO1/TDO inhibitors
Covalent IDO inhibitors
Market Segment by Applications, can be divided into
Metastatic Melanoma
Metastatic Pancreatic Cancer
mCRPC
Malignant Glioma
Astrocytoma
Breast Cancer
There are 15 Chapters to deeply display the global IDO Inhibitors market.
Chapter 1, to describe IDO Inhibitors Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of IDO Inhibitors, with sales, revenue, and price of IDO Inhibitors, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of IDO Inhibitors, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, IDO Inhibitors market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe IDO Inhibitors sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
